Saturday 31 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

273.71 1.49 −0.54%

Follow JNJ

Alert me

Market cap: $662.5B
P/E: 31.7×
Fwd P/E: 38.6×
Dividend yield: 1.93%
F-score: 3/9
Altman Z: 4.78
Beneish M: −2.26
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Filings

Johnson & Johnson (JNJ) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Innovative Medicine	60,401	64.12%
MEDTECH	33,792	35.88%
Gross margin		67.88%
Operating margin		34.59%
Pre-tax margin		34.59%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Innovative Medicine	60,401 64.12%	56,964 64.13%	54,759 64.30%	52,563 65.71%	51,680 65.63%	45,175 54.70%	42,198 51.42%	40,734 49.93%	36,256 47.42%	33,464 46.55%
MEDTECH	33,792 35.88%	31,857 35.87%	30,400 35.70%	27,427 34.29%	27,060 34.37%	22,959 27.80%	25,963 31.64%	26,994 33.09%	26,592 34.78%	25,119 34.94%
Consumer	—	—	—	—	—	14,450 17.50%	13,898 16.94%	13,853 16.98%	13,602 17.79%	13,307 18.51%
Revenue	94,193	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Innovative Medicine	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
MEDTECH	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
United States	53,752 57.07%	50,302 56.63%	46,444 54.54%	41,981 52.48%	40,640 51.61%	43,133 52.23%	42,097 51.30%	41,884 51.34%	39,863 52.14%	37,811 52.60%
Europe	21,535 22.86%	20,212 22.76%	20,410 23.97%	20,664 25.83%	20,595 26.16%	18,980 22.98%	18,466 22.50%	18,753 22.99%	17,126 22.40%	15,770 21.94%
Asia-Pacific, Africa	14,031 14.90%	13,593 15.30%	13,756 16.15%	13,237 16.55%	13,578 17.24%	15,136 18.33%	15,555 18.96%	14,831 18.18%	13,420 17.55%	12,575 17.49%
Western Hemisphere, excluding U.S.	4,875 5.18%	4,714 5.31%	4,549 5.34%	4,108 5.14%	3,927 4.99%	5,335 6.46%	5,941 7.24%	6,113 7.49%	6,041 7.90%	5,734 7.98%
Non-US	40,441	38,519	38,715	38,009	38,100	39,451	39,962	39,697	36,587	34,079
Revenue	94,193	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.